EPISODE · Jan 23, 2025 · 0 MIN
Ubrogepant Reduced Migraine-Related Limitations When Taken During the Prodrome Phase
from Migraine Minute News Update
According to a study published in Neurology, when compared to placebo, this gepant led to significantly greater ability to function normally and a greater reduction in activity limitation when taken during the prodrome phase of an attack. Molly O'Brien has the details in this Migraine Minute News Update. Read More: https://bit.ly/3BY2J9d
Embed this episode
NOW PLAYING
Ubrogepant Reduced Migraine-Related Limitations When Taken During the Prodrome Phase
0:00
0:55
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Migraine Minute News Update?
This episode is 0 minutes long.
When was this Migraine Minute News Update episode published?
This episode was published on January 23, 2025.
Can I download this Migraine Minute News Update episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!